Current filters:

IsentressNorth America

Merck gains expanded Isentress indication; lowers price of drug for ADAps


In two pieces of HIV/AIDS-related news for US drugs giant Merck & Co (NYSE: MRK), the company’s…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricingRegulation

Merck slammed over drug pricing


In another swipe at US pharma giant Merck & Co (NYSE: MRK), the AIDS Healthcare Foundation (AHF) has…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricing

AHF takes campaign to Merck & Co’s home town with AIDS banners protesting high cost of Isentress


As part of its ongoing campaign to lower AIDS drug prices and increase access, the USA-based AIDS Healthcare…

Anti-viralsIsentressMerck KGaANorth AmericaPharmaceuticalPoliticsPricingRaltegravir Tablets

AIDS Healthcare Foundation bans Merck & Co’s drug reps from its clinics


The AIDS Healthcare Foundation (AHF), the largest global AIDS organization which operates free AIDS treatment…

Anti-viralsIsentressMerck KGaANorth AmericaPharmaceuticalPricingRaltegravir Tablets

Positive Ph III findings for Merck & Co’s HIV/AIDS drug Isentress


The online edition of The Lancet has published results from a 48-week Phase III study of treatment-naive…

EfavirenzEmtricitabineEmtrivaImmunologicalsIsentressMerck KGaANorth AmericaPharmaceuticalRaltegravir TabletsSustiva

Back to top